webinar register page

Webinar banner
ROTH Webinar - Jounce Therapeutics (JNCE) - Oct 13, 2020 – 11:00 AM (ET) / 8:00 AM (PT)

00:59:00

Oct 13, 2020 10:36 AM

* Required information
Loading

By registering, I agree to the Privacy Statement and Terms of Service.

Register

Speakers

Richard Murray, Ph.D.
President & CEO @Jounce Therapeutics (JNCE)
Richard Murray has served as Chief Executive Officer and President of Jounce Therapeutics, along with sitting on the Board of Directors, since July, 2014. He brings to Jounce more than two decades of biologics R&D leadership and experience moving product candidates through development to commercialization for both startup biotechnology and large pharmaceutical companies. Dr. Murray joined Jounce from Merck, where he most recently served as senior vice president, biologics & vaccines research. There, he was responsible for the advancement of protein therapeutics and vaccines across a breadth of therapeutic areas, from discovery through development and manufacturing, including Merck’s immunotherapy programs. Prior to joining Merck, Dr. Murray provided strategic and operational guidance to protein therapeutic biotech companies and served as an advisor to venture capital and life science investors. (www.jouncetx.com - 9/23/2020)
Elizabeth Trehu, M.D.
CMO @Jounce Therapeutics
Elizabeth (Beth) Trehu, M.D., FACP, brings to Jounce more than 30 years of clinical experience, including 20 years in the biotech industry leading translational and integrated hematology and oncology drug development. Dr. Trehu designed and ran her first immunotherapy cancer trials in the early 90’s as a fellow and assistant professor of medicine at Tufts University School of Medicine, where she conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group. Dr. Trehu joined Jounce from Promedior, Inc., where she served as the chief medical officer. In this role, she led the creation and implementation of clinical development plans for Promedior’s lead macrophage product candidate, PRM-151, which led to the acquisition of Promedior by Roche in 2020. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals. (www.jouncetx.com -9/23/2020)